Scarica l'app Stockscreener
7.39
1.79%
0.13
Pre-mercato:
7.56
0.17
+2.30%
Precedente Chiudi:
$7.26
Aprire:
$7.35
Volume 24 ore:
2.90M
Relative Volume:
1.74
Capitalizzazione di mercato:
$562.97M
Reddito:
-
Utile/perdita netta:
$-168.09M
Rapporto P/E:
-3.4055
EPS:
-2.17
Flusso di cassa netto:
$-138.01M
1 W Prestazione:
+1.79%
1M Prestazione:
-17.98%
6M Prestazione:
-64.73%
1 anno Prestazione:
-49.69%
Intervallo 1D:
$7.20
$7.435
Intervallo di 1 settimana:
$7.02
$7.66
Portata 52W:
$6.98
$24.17
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Confronta KURA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
7.39 | 562.97M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Assenagon Asset Management S.A. Sells 146,879 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Up 17.4% in December - MarketBeat
JPMorgan Chase & Co. Boosts Stake in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Harbor Capital Advisors Inc. Boosts Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology secures new headquarters in San Diego - Investing.com India
Kura Oncology secures new headquarters in San Diego By Investing.com - Investing.com Australia
Kura Oncology stock hits 52-week low at $8.38 amid market challenges - Investing.com Nigeria
Kura Oncology (NASDAQ:KURA) Sets New 12-Month LowTime to Sell? - MarketBeat
Brokers Set Expectations for Kura Oncology FY2029 Earnings - Defense World
Brokers Offer Predictions for Kura Oncology FY2029 Earnings - MarketBeat
BlackRock, Inc. Increases Stake in Kura Oncology Inc - GuruFocus.com
Long Term Trading Analysis for (KURA) - Stock Traders Daily
Scotiabank Cuts Kura Oncology (NASDAQ:KURA) Price Target to $10.00 - MarketBeat
Kura Oncology announces executive changes and settlement By Investing.com - Investing.com Australia
Kura Oncology announces executive changes and settlement - Investing.com India
Kura Oncology appoints new CMO and CSO By Investing.com - Investing.com Australia
Kura Oncology (NASDAQ:KURA) Sets New 1-Year LowTime to Sell? - MarketBeat
Kura Oncology Announces Leadership Changes and Appointments - MSN
Kura Oncology Promotes New Chief Medical Officer - MarketWatch
Kura Oncology appoints new CMO and CSO - Investing.com
Kura Oncology Announces Senior Executive Promotions - The Manila Times
Kura Oncology (NASDAQ:KURA) Hits New 12-Month LowHere's Why - MarketBeat
Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover - MSN
Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Buy” by Analysts - Defense World
Objective long/short (KURA) Report - Stock Traders Daily
Kura Oncology (NASDAQ:KURA) Sets New 12-Month Low – Here’s What Happened - Defense World
Kura Oncology's Stock Sinks To US$8.94, But Insiders Sold Even Lower - Simply Wall St
Kura Oncology (NASDAQ:KURA) Reaches New 12-Month LowWhat's Next? - MarketBeat
Kura Oncology stock hits 52-week low at $8.83 amid market challenges - Investing.com Australia
Kura Oncology expands stock option plan - Investing.com India
Kura Oncology expands stock option plan By Investing.com - Investing.com UK
Kura Oncology (NASDAQ:KURA) Reaches New 52-Week LowWhat's Next? - MarketBeat
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade) (NASDAQ:KURA) - Seeking Alpha
(KURA) Proactive Strategies - Stock Traders Daily
Kura, Kyowa highlight positive combo data for ziftomenib - BioWorld Online
Kura Oncology's SWOT analysis: ziftomenib's promise buoys stock outlook By Investing.com - Investing.com UK
Kura Oncology's SWOT analysis: ziftomenib's promise drives stock outlook By Investing.com - Investing.com South Africa
Kura Oncology's SWOT analysis: ziftomenib's promise drives stock outlook - Investing.com India
Kura Oncology's SWOT analysis: ziftomenib's potential reshapes cancer stock landscape - Investing.com Canada
Kura Oncology’s (KURA) Overweight Rating Reaffirmed at Cantor Fitzgerald - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Call Transcript - MSN
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting - The Manila Times
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):